Data as of May 24
| +0.02 / +0.24%|
The 5 analysts offering 12-month price forecasts for PDL BioPharma Inc have a median target of 7.00, with a high estimate of 8.50 and a low estimate of 6.00. The median estimate represents a -16.37% decrease from the last price of 8.37.
The current consensus among 6 polled investment analysts is to Hold stock in PDL BioPharma Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.